louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04932694: Optimizing Function Outcomes After Bariatric Surgery With Core Stabilization Training: A Randomized Controlled Study
Official title: Optimizing Function Outcomes After Bariatric Surgery With Core Stabilization Training: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bariatric Surgery
Surgery
Keywords: Bariatric surgery
Core training
Stabilization exercises
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Batterjee Medical College
name: Taif University
First posted: 2021-06-21
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Bariatric surgery has been reported to be the most effective treatment option for losing and maintaining body weight and improving comorbidities and mortality associated with morbid obesity. Nevertheless, even though physical activity is recommended to optimize bariatric surgery results. Very little is known, about whether engaging in an exercise program after surgery can provide additional improvement in health outcomes. While to date there are relatively few researches studied the effect of exercise in patients who have undergone bariatric surgery.

Detailed description: This study will investigate the effect of core stabilization exercise on patients who underwent bariatric suergery.

Eligibility criteria: Inclusion Criteria:

* Both male and female
* age ranged from 18-25 years old,
* at least 6 months after BS

Exclusion Criteria:

* Patients with nerve root compression
* spine disorders
* spinal fracture
* previous spinal surgery
* pregnancy
* lower limb injury
* Any contraindication to the exercise therapy

Primary outcomes:
measure: Core endurance tests
timeFrame: 2 months
measure: Flexor extensor isokinetic torque
timeFrame: 2 months
Secondary outcomes:
measure: Balance assessment
timeFrame: 2 months
measure: 6 min walking test
timeFrame: 2 months
measure: Function Assessment
timeFrame: 2 months
measure: Trunk sense of position
timeFrame: 2 months
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Olfat Ibrahim Ali
state: Dokki
city: Jeddah
country: Saudi Arabia
facility: Olfat Ibrahim Ali
Study officials:
affiliation: Cairo University
name: Olfat I Ali, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01104194: Effects of Fish-oil on Mood and Cognitive Functions of Healthy Individuals
Official title: The Effects of Omega-3 Fatty Acids Dietary Supplements (Fish-oil) on Mood and Cognitive Functions of Healthy Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Keywords: depression
cognition
heart rate variability
omega-3 fatty acids
Depression (in remission) (vulnerability to depression)
Lead sponsor: Leiden University Medical Center
Sponsor class: OTHER
First posted: 2010-04-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators recently found a positive effect of omega-3 supplements on cognitive function in healthy individuals after 4 weeks (J of Psychopharmacology 2009, 23: 831-840). The investigators hypothesize that 4 weeks consumption of omega-3 supplements in previously depressed individuals will positively affect their cognitive functions.

Secondly, low Heart Rate Variability (HRV) is a risk factor for cardiovascular disease. Some studies have found low HRV in patients with depression. No studies have investigated the effects of omega-3 fatty acid supplements on Heart Rate Variability in individuals with a history of depression. The investigators will test the hypotheses that omega-3 supplements lead to an improvement of heart rate variability indices in healthy volunteers with a history of depression.


Eligibility criteria: Inclusion Criteria:

* Dutch-speaking men and women
* Normal weight (BMI between 18 and 27).
* Regular diets, not containing fish more than once a week.
* History of depression (at least one major depressive episode in the past).

Exclusion Criteria:

* Currently more than mildly depressed (BDI-II-NL score higher than 19, or score on the suicidality item of this scale higher than 1).
* Current or past psychosis
* Current substance abuse or past substance dependence
* Smoking or current use of soft drugs (current = month prior to study till completion)
* Any hard drug use (lifetime)
* More than 3 alcoholic consumptions/day

Participants will be asked to keep their dietary habits constant throughout the study.

Primary outcomes:
measure: Cognition
timeFrame: 4 weeks
measure: Heart Rate Variability
timeFrame: 4 weeks
Secondary outcomes:
measure: Mood states
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Leiden University
state: ZH
Study officials:
References:
Clinical trial NCT00042094: Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®
Official title: A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Smallpox
Keywords: Smallpox
Smallpox Vaccine
Vaccinia
Lead sponsor: DynPort Vaccine Company LLC, A GDIT Company
Sponsor class: INDUSTRY
First posted: 2002-07-26
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will evaluate the safety and efficacy of both Dryvax® and the new cell-cultured vaccine (CCSV) in a comparative fashion. Across 3 cohorts, 150 vaccinia-naive volunteers will be randomly assigned to receive either CCSV (100 volunteers) or Dryvax® (50 volunteers) in a blinded fashion. Subjects will be followed closely for up to 6 months and a subgroup of volunteers will be followed up to 3 years in order to evaluate the duration of immunity following vaccination. Another cohort will enroll 100 vaccinia-experienced volunteers and randomly assign them to receive either CCSV (50 volunteers) or Dryvax® (50 volunteers) and a sub group will be followed up to 3 years. A fifth cohort will enroll 100 vaccinia-naive volunteers and randomly assign them to receive different dilutions of CCSV (1:1, 1:5, 1:25, and 1:50).


Eligibility criteria: * Have never received smallpox vaccine or previously received an experimental smallpox vectored vaccine (for vaccinia-naive cohorts only)
* Have been previously vaccinated within the last 10 years (vaccinia-experienced cohort only)
* Must agree to have blood samples banked for future research testing
* Have not participated in any clinical trial using investigational product within past month
* No current or past history of exfoliative skin problems
* Not have regular contact with children under 3 years of age until scab at site of vaccination has fallen off (around 21 days or 3 weeks after vaccination)
* Do not have a positive test for HIV virus, hepatitis C virus, or hepatitis B surface antigen
* Are not a health care worker caring for newborns, patients that are immunocompromised or have skin that is adversely altered
* Will not engage in direct patient care until immunization scab falls off (around 21 days or 3 weeks after vaccination) if health care worker

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky Medical Center
state: Kentucky
Study officials:
References:
Clinical trial NCT03533894: French Observational Study With Colic Capsule
Official title: French Observational Study With Colic Capsule
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colic Capsule Interest
Lead sponsor: Hôpital Edouard Herriot
Sponsor class: OTHER
First posted: 2018-05-23
Enrollment: 680
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: men or women with colic endoscopy problems

Brief summary: colic capsule usings with patients without possible colic endoscopy


Eligibility criteria: Inclusion Criteria:

* anesthesia not possible
* incomplete colic endoscopy
* colic endoscopy refused

Exclusion Criteria:

* none

Primary outcomes:
measure: number of polyps or lesions
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06821594: Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts at Tertiary Care Hospital in Karachi.
Official title: Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts.
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: EARLY_PHASE1
Conditions: Cutaneous Warts
Keywords: Cutaneous warts
furosemide
digoxin
Lead sponsor: Jinnah Postgraduate Medical Centre
Sponsor class: OTHER_GOV
First posted: 2025-02-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.

Detailed description: Cutaneous warts are benign growth caused by human papilloma virus. Virus have more than 100 types of which few are responsible for cutaneous disease. Both injection furosemide and digoxin cause decrease intracellular potassium levels by interacting with cell membrane ion co-transporters (Na+/K+-ATPase and Na+-K+-2Cl-co-transporter-1) thereby causing delay in viral replication. The purpose of study is to evaluate the effects of both furosemide and digoxin given 0.2 ml once weekly for five weeks on viral warts.

Eligibility criteria: Inclusion Criteria:

1. Patients presenting with greater than or equal to two warts
2. Either gender.
3. Age 18 - 60 years. -

Exclusion Criteria:

1. Pregnant or lactating women.
2. Patient not giving informed consent.
3. Patient received any treatment in the last 3 months period.
4. Patient with acute illness and immuno-suppressive disease.
5. Patient taking immuno-suppressive drugs.
6. Patient having hypersensitivity to any investigational medicine.
7. Patient having cutaneous warts on face and genitals.
8. Patient having cardiovascular disease.
9. Patient having renal disease. -

Primary outcomes:
measure: Size of cutaneous wart
timeFrame: 5 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Jinnah Postgraduate Medical Centre
state: Sindh
Study officials:
References:
Clinical trial NCT02891694: Metalloproteinases and Recurrent Corneal Erosion Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Recurrent Corneal Erosion Syndrome
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2016-09-07
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Recurrent Corneal Erosion Syndrome and control patients (undergoing photorefractive surgical keratectomy)

Brief summary: Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. This could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane.

The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3 in the RCE syndrome.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years old
* Recurrent Corneal Erosion Syndrome, with - failure of medical treatment and therapeutic photokeratectomy scheduled
* Photorefractive surgical keratectomy (control patients)

Exclusion Criteria:

* Opposition to participation in the study
* Known pregnancy or breast-feeding patient
* No medical insurance coverage

Primary outcomes:
measure: expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) in epithelial cells
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Opthalmologique A de Rothschild
Study officials:
affiliation: Fondation OPH A de Rothschild
name: Eric GABISON, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03670394: Capillary Refill for Assessment of Dehydration
Official title: Capillary Refill to Detect Dehydration in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dehydration in Children
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2018-09-13
Enrollment: 178
Sex: ALL
Minimum age (years): 6
Maximum age (years): 10
Standard ages: CHILD
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients presenting to the pediatric ER at OHSu.

Brief summary: Capillary refill is used clinically to assess multiple things in children. This is a prospective observational study of the correlation between capillary refill time and degree of dehydration in children seen in a pediatric ED.

Detailed description: All patient presenting to the pediatric ER at OHSU less than 10 years are eligible to be enrolled if being seen for a condition putting them at risk for dehydration including emesis, diarrhea, etc. Children will have their capillary refill time measured and then sent home with a digital scale to track their weight. This will serve as the standard for calculating percent dehydration. When a patient has reached a stable weight at 1 week we will assume this is their healthy weight. There is no intervention in the study.

Eligibility criteria: Inclusion Criteria:

* All children with chief complaint of diarrhea, emesis, nausea, abdominal pain

Exclusion Criteria:

* Any child with chronic cardiac or pulm disease, raynauds syndrome, bilateral upper extremity trauma, previously enrolled in the study, already received IVF in the previous 48hrs, surgery within 1week, osteogenesis imperfecta.

Primary outcomes:
measure: Capillary Refill time
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: OHSU
state: Oregon
Study officials:
affiliation: Oregon Health and Science University
name: David Sheridan, MD MR
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01383694: Effect Of Piperine In Patients With Oropharyngeal Dysphagia
Official title: Effect of Natural Agonists of TRPV1 in the Treatment of Functional Oropharyngeal Dysphagia in Neurological Diseases and the Elderly: Piperine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Deglutition Disorders
Lead sponsor: Hospital de Mataró
Sponsor class: OTHER
First posted: 2011-06-28
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Piperine acts on the oropharyngeal TRPV1, increasing sensory input and the release of substance P. These actions may accelerate the oropharyngeal swallow response, improving the swallowing of dysphagic patients.


Eligibility criteria: Inclusion Criteria:

* Age\>18
* History of swallowing difficulties associated with aging and/or neurological diseases (neurodegenerative or non-progressive neurological diseases)
* Study explained and written subject information given
* Informed consent signed

Exclusion Criteria:

* Patients suffering idiosyncratic phenomena or who are allergic to any medication, especially iodinated contrast media
* Patients suffering major respiratory disease or undergoing any type of surgery in the three months prior to the study
* Patients with a background of alcohol dependence or other drug dependence
* Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of the study

Primary outcomes:
measure: Safety of swallow
timeFrame: 15 minutes
Secondary outcomes:
measure: Efficacy of swallow
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Mataró
country: Spain
facility: Hospital de Mataró
state: Barcelona
Study officials:
References:
Clinical trial NCT05102994: Mutation Detection for VRL
Official title: The Diagnostic Value of Mutation Detection for VRL
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Vitreoretinal Lymphoma
Uveitis
Keywords: Vitreoretinal lymphoma
Uveitis
intraocular fluid
mutation
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2021-11-02
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: suspected VRL or uveitis patients attending to our clinic

Brief summary: Vitreoretinal lymphoma (VRL) is a rare but aggressive masquerade syndrome, which would be easily confused with uveitis. The diagnostic gold standard remains the pathologic examination of ocular specimen with invasiveness and low sensitivity. To improve the safety and accuracy of VRL diagnosis, alternative techniques using intraocular fluid (IOF) samples are emerging. In this study, we aimed to test the diagnostic value of mutation analysis for VRL

Detailed description: chest CT, urinalysis, kidney, and liver function were routinely checked.

IL-10/IL-6 ratio, genetic mutation analysis and samples were IGH gene rearrangements were reviewed and analyzed retrospectively.

The diagnoses were identified after careful evaluation of treatment effects in follow-up. The diagnostic value including sensitivity, specificity, positive and negative predictive values, and test efficiency of genetic mutation analysis in diagnosing VRL were analyzed.

Furthermore, a validation group of patients including VRL and uveitis was selected to validate the diagnostic value of mutation analysis in the diagnosis of VRL. All the patients signed an informed consent and institutional review board approval was obtained. The study was performed in accordance with the tenets of the Declaration of Helsinki.

Eligibility criteria: Inclusion Criteria:

* suspected VRL patients who had intraocular fluid for mutation test. And got a clear diagnose of VRL or uveitis afther having dianostic tests and follow-up treatment

Exclusion Criteria:

* suspected VRL patients who lost in follow-up without a definitive diagnose, or whoever reluctance to participate our study

Primary outcomes:
measure: the result of mutation test
timeFrame: at baseline, before treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center, Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Zhongshan Ophthalmic Center, Sun Yat-sen University
name: Dan D Liang, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02655094: Unilateral Pulmonary Edema After Minimal-invasive Mitral Valve Surgery
Official title: Unilateral Pulmonary Edema After Minimal-invasive Mitral Valve Surgery: a Retrospective Single Center Observation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Edema
Keywords: minimal-invasive surgery, mitral valve
Lead sponsor: University Hospital Schleswig-Holstein
Sponsor class: OTHER
First posted: 2016-01-13
Enrollment: 256
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Collective of patients with relevant mitral valve disease scheduled for minimal-invasive mitral valve repair or replacement

Brief summary: Unilateral pulmonary edema after minimal-invasive mitral valve surgery is a rare but in some cases severe complications, sometimes causing extracorporeal life support. The investigators have observed over several years 5 cases of instantaneous postoperative severe pulmonary edema. This is a retrospective analysis of over 200 minimal-invasive mitral valve surgery procedure.

Detailed description: Unilateral pulmonary edema after minimal-invasive mitral valve surgery is a rare but in some cases severe complications, sometimes causing extracorporeal life support. The investigators have observed over several years 5 cases of instantaneous postoperative severe pulmonary edema. After having studied the available literature on this particular topic the investigators have decided to prepare a retrospective analysis of over 200 minimal-invasive mitral valve surgery procedure focusing on radiological and clinical signs of unilateral pulmonary edema.

Eligibility criteria: Inclusion Criteria:

* \>= 18 years of age

Exclusion Criteria:

* urgent surgery

Primary outcomes:
measure: Unilateral right sided pulmonary edema or congestion after surgery
timeFrame: Postoperatively within the first 12h after admission to intensive care unit
Secondary outcomes:
Other outcomes:
Locations:
city: Kiel
country: Germany
facility: universitätsklinikum Schleswig-Holstein
state: Schleswig-Holstein
Study officials:
affiliation: University Hospital Schleswig-Holstein
name: Jochen Renner, PD Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Renner J, Lorenzen U, Borzikowsky C, Schoeneich F, Cremer J, Haneya A, Hensler J, Panholzer B, Huenges K, Broch O. Unilateral pulmonary oedema after minimally invasive mitral valve surgery: a single-centre experience. Eur J Cardiothorac Surg. 2018 Apr 1;53(4):764-770. doi: 10.1093/ejcts/ezx399.